Taking the Tension out of the Portal System: An Approach to the Management of Portal Hypertension in the 1990s

References

• Mac Mathuna P, Vlavianos P, Westaby D, Williams R. The pathophysiology of portal hypertension. Dig Dis 1990, in press
   Google Scholar
• Whipple AO. The problem of portal hypertension in relation to hepatosplenopathies. Ann Surg 1945; 122: 449–475
   PubMed Web of Science ®Google Scholar
• McLndoe AH. Vascular lesions of portal hypertension. Arch Path Lab 1928; 5: 23–27
   Google Scholar
• Schaffner F, Popper H. Capillarization of the hepatic sinusoids in man. Gastroenterology 1963; 44: 239–251
   PubMed Web of Science ®Google Scholar
• Popper H, Paronetto F, Schaffner F, Perez V. Studies on hepatic fibrosis. Lab Invest 1961; 10: 265–278
   PubMedGoogle Scholar
• Orrego H, Blendis L M, Crossley I R, et al. Correlation of intrahepatic pressure with collagen in the Disse space and hepatomegaly in humans and in the rat. Gastroenterology 1981; 80: 546–556
   PubMedGoogle Scholar
• Blendis L M, Orrego H, Crossley I R, et al. The role of hepatocyte enlargement in hepatic pressure in cirrhotic and noncirrhotic alcoholic liver disease. Hepatotology 1982; 2: 539–546
   PubMedGoogle Scholar
• Reynolds T B, Geller H M, Kuzma O T, Redeker AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960; 263: 734–739
   PubMedGoogle Scholar
• Crossley I R, Westaby D, Williams R. Portal hypertension. Liver and biliary disease, R Wright, GH Milward-Sadler. Bailliere Tindall, London 1985; 1291–1293
   Google Scholar
• Boyer JL. Is colchinine effective therapy for cirrhosis?. N Engl J Med 1988; 318: 1751–1752
   PubMedGoogle Scholar
• McClain C J, Cohen DA. Increased tumour necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9: 349–351
   PubMed Web of Science ®Google Scholar
• Reichen J, Le M. Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 1986; 78: 448–455
   PubMed Web of Science ®Google Scholar
• Ballet F, Chretien Y, Rey C, et al. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused liver. J Pharmacol Exp Ther 1988; 244: 283–289
   PubMed Web of Science ®Google Scholar
• Bhathal P S, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325–337
   PubMed Web of Science ®Google Scholar
• Marteau P, Ballet F, Chazouilleres O, et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology 1989; 9: 820–823
   PubMedGoogle Scholar
• Kiel J W, Pitts V, Benoit J N, et al. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985; 248: G192–G195
   Google Scholar
• Freeman J G, Barton J R, Record CO. Effects of isosorbide dinitrate, verapramil and labetolol on portal pressure in cirrhosis. Br Med J 1985; 291: 561–562
   PubMedGoogle Scholar
• Navasa M, Bosch J, Reichen J, et al. Effect of verapamil on hepatic and systemic haemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988; 8: 850–854
   PubMed Web of Science ®Google Scholar
• Mac Mathuna P, O'Reilly T, Kelleher D, et al. The effect of calcium channel blockade with nifedipine on splanchnic and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1987; 1: 639–642
   PubMedGoogle Scholar
• Blei A T, Granger D, Fung H L, et al. Organic nitrates in portal hypertension. Eur Heart J 1988; 9A: 205–211
   Google Scholar
• Garcia-TsaoG Hanson J S, Groszmann RJ. Portal haemodynamics during nitroclycerin administration in cirrhotic patients. Hepatology 1987; 7: 805–808
   PubMedGoogle Scholar
• Navasa M, Chesta J, Bosch J, et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Gastroenterology 1989; 96: 1110–1119
   PubMed Web of Science ®Google Scholar
• Garcia-Pagan J C, Bosch J, Navasa M, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate (Is-5-Mn) to propranolol administration on cirrhosis. J Hepatol, 188(7)S34
   Google Scholar
• Mac Mathuna P, O'Reilly T, Kelleher D, et al. Combined vasodilatation and /3-adrenergic blockade therapy in portal hypertension. Clin Sci 1986; 15: 74P
   Google Scholar
• Moreau R, Lee S S, Hadengue A, et al. Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: effects of vasoactive drugs. Hepatology 1989; 9: 427–432
   PubMed Web of Science ®Google Scholar
• Brenner B M, Troy J L, Ballermann BJ. Endothelium dependent vascular response: mediators and mechanisms. J Clin Invest 1989; 84: 1373–1378
   PubMed Web of Science ®Google Scholar
• Murad F. Cyclic guanosine monophosphate as a mediator of vasodilatation. J Clin Invest 1986; 78: 1–5
   PubMed Web of Science ®Google Scholar
• Cummings S A, Groszmann R J, Kaumann A. Hypersensitivity of mesenteric veins to 5-hydroxy-tryptamine and ketanserin-induced reduction in portal pressure in portal hypertensive rats. Br J Pharmacol 1986; 89: 501–513
   PubMedGoogle Scholar
• Hadengue A, Lee S S, Moreau R, et al. Beneficial haemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hepatology 1987; 7: 644–647
   PubMedGoogle Scholar
• Vorobioff J, Garcia-Tsoa G, Groszmann R J, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989; 9: 88–91
   PubMed Web of Science ®Google Scholar
• Hadengue A, Moreau R, Cerini R, et al. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology 1989; 9: 83–87
   PubMedGoogle Scholar
• Grange J D, Jaillon P, Noblinski B, et al. La pentoxifylline: un traitement potential des cirrhoses avec hypertension portale. Gastroenterol Clin Biol 1987; 11: 161
   Google Scholar
• Mac Mathuna P, Vlavianos P, Wendon J, Westaby D, Williams R. Haemodynamic and metabolic effects of adenosine receptor blockade in cirrhosis. Gut 1990; 31: A627
   Google Scholar
• Ezzat W, Lautt WW. Hepatic arterial pressure-flow autoregulation is adenosine regulated. Am J Physiol 1987; 252: H836–H845
   PubMed Web of Science ®Google Scholar
• Lapointe DS, Olson MS. Alteration of heptic tissue space by platelet activating factor and phenylephrine. Hepatology 1989; 9: 278–284
   PubMedGoogle Scholar
• Yanagisawa M, Kurimara H, Kumura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415
   PubMed Web of Science ®Google Scholar
• Zimmon D S, Kessler RE. Effect of portal venous blood flow diversion on portal pressure. J Clin Invest 1980; 65: 1388–1397
   PubMedGoogle Scholar
• Pizcueta M P, de Lacy A M, Kravetz D, Bosch J, Rodes J. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats. Hepatology 1989; 10: 953–957
   PubMedGoogle Scholar
• Blei A T, Gottstein J. Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic responses. Hepatology 1986; 6: 107–111
   PubMedGoogle Scholar
• Schrier R W, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilatation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151–1157
   PubMed Web of Science ®Google Scholar
• Benoit J N, Barrowman JA, Harper S L, et al. Role of humoral factors in the intestinal hyperaemia associated with portal hypertension. Am J Physiol 1984; 247: G486–G493
   Google Scholar
• Thornton J R, Dean H G, Losowsky MS. Do increased catecholamines and plasma methionine enkephalin in cirrhosis promote bleeding oesophageal varices?. Q J Med 1988; 68: 541–551
   PubMedGoogle Scholar
• Prostaglandins and the splanchnic circulation. Proc Soc Exp Biol Med, RH Gallavan, Jacobson, 1982; 170: 391–397
   Google Scholar
• Wernze H, Tittor W, Goerig M. Release of prostanoids into the portal vein and hepatic vein in patients with chronic liver disease. Hepatology 1986; 6: 911–916
   PubMedGoogle Scholar
• Minuk G Y, MacCannell KL. Is the hypotension of cirrhosis a GABA-mediated process?. Hepatology 1988; 8: 73–77
   PubMedGoogle Scholar
• Berne RM. Criteria for the involvement of adenosine in the regulation of blood flow. Methods in adenosine research, DM Paton. Plenum Press, New York 1986
   Google Scholar
• Sparks H V, Gorman MW. Adenosine in the local regulation of blood flow: current controversies. Topics and perspectives in adenosine research, E Gerback, BF Becker. Springer-Verlag, Heidelberg 1987
   Google Scholar
• Miyamoto K, French SW. Hepatic adenine nucleotide metabolism measured in vivo in rats fed etha-nol and a high fat-low protein diet. Hepatology 1988; 8: 52–60
   Google Scholar
• Arai M, Leo M A, Nakano M, et al. Biochemical and morphological alterations of baboon hepatic mitochondria after chronic ethanol consumption. Hepatology 1984; 4: 165–174
   PubMed Web of Science ®Google Scholar
• Oldershaw P, Barnes P J. Adenosine in heart and lung disease Postgrad. Med J 1988; 64: 820–828
   Google Scholar
• Bomzon A, Blendis LM. Vascular reactivity in experimental portal hypertension. Am J Physiol 1987; 252: G158–G162
   PubMed Web of Science ®Google Scholar
• Bemardi M, Trevisiani F, Santani C, et al. Plasma norepinephrine, weak neurotransmitters and renin activity during active tilting in liver cirrhosis; relationship with cardiovascular homeostasis and renal function. Hepatology 1983; 3: 56–64
   PubMedGoogle Scholar
• Vianna A, Hayes P S, Moscoso G, et al. Normal venous circulation of the gastroesophageal junction. Gastroenterology 1987; 3: 876–879
   Google Scholar
• Polio J, Groszmann RJ. Haemodynamic factors involved in the development and rupture of oesophageal varices: a pathophysiologic approach to treatment. Sem Liver Dis 1986; 6: 318–329
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao E, Groszmann R J, Fisher R L, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419–424
   PubMed Web of Science ®Google Scholar
• Lebrec D, de Fleury P, Rueff B, et al. Portal hypertension, size of oesophageal varices and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980; 79: 1139–1144
   PubMed Web of Science ®Google Scholar
• Vinel J P, Cassigneul J, Levade M, et al. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology 1986; 6: 116–117
   PubMed Web of Science ®Google Scholar
• Vlavianos P, Gimson A ES, Hayallar K, Mac Mathuna P, Westaby D, Williams R. Prognostic significance of systemic and splanchnic haemodynamic parameters in patients with cirrhosis and previous variceal bleeding. Gut 1990; 31: A592
   Google Scholar
• Beppu K, Inokuchi K, Koyanogi N, et al. Prediction of variceal haemorrhage by esophageal endoscopy. Gastro Endosc 1981; 27: 213–218
   PubMed Web of Science ®Google Scholar
• The North Italian Endoscopic Club for the Study and Treatment of Varices Oesophageal. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicentre study. N Engl J Med 1988; 319: 983–989
   PubMed Web of Science ®Google Scholar
• Pugh R NH, Murray-Lyon I M, Dawson D L, Pie-Troni M C, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–649
   PubMed Web of Science ®Google Scholar
• Burroughs A K, d'Heygere F, McLntyre N. Pitfalls in studies of prophylactic therapy for variceal bleeding in cirrhotics. Hepatology 1986; 6: 1407–1413
   PubMed Web of Science ®Google Scholar
• Mac Mathuna P, Westaby D, Williams R. Portal hypertension. Liver and biliary disease, R Wright, GH Milward-Sadler. Bailliere Tindall, London 1990, in press
   Google Scholar
• The Italian Multicentric Project for Propranolol in the Prevention of Bleeding. Propranolol for prevention of bleeding in cirrhotic patients with large varices: a prophylactic multicentric randomised clinical trial. Hepatology, 198: 8, 1–5
   Google Scholar
• Pascal J P, Cales P. Multicenter Study Group. Propranolol in the prevention of the first upper gastrointestinal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: 856–861
   PubMed Web of Science ®Google Scholar
• Bosch J, Groszmann R J, Grace N, et al. Propranolol in the prevention of the first hemorrhage from esophageal varices: results of a randomised double blind cooperative clinical trial. J Hepatol 1988; 7: S12
   Google Scholar
• Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomised study. Hepatology 1988; 8: 6–9
   PubMed Web of Science ®Google Scholar
• Lebrec D, Poynard T, Capron J P, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis: a randomised trial. J Hepatol 1988; 7: 118–125
   PubMed Web of Science ®Google Scholar
• Pagliaro L, Burroughs A K, Sorensen T IA, et al. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2: 71–84
   Google Scholar
• Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 1204–1209
   PubMed Web of Science ®Google Scholar
• Gerbes A L, Remien J, Jungst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of β2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409–1411
   PubMed Web of Science ®Google Scholar
• Hayes P C. Safety of propranolol in portal hypertension. Drugs 1989; 37: 52–61
   PubMedGoogle Scholar
• Reding P. Risk of hepatic encephalopathy in patients taking propranolol for portal hypertension [Letter]. Lancet 1982; 2: 550
   PubMedGoogle Scholar
• Cales P, Nicolas M P, Guell A, et al. Propranolol does not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy. Hepatolgy 1989; 9: 439–442
   PubMedGoogle Scholar
• Mac Mathuna P, Vlavianos P, Wendon J, Gove C D, Westaby D, Williams R. Propranolol does not adversely affect hepatic redox state or oxygen consumption in advanced alcoholic liver disease. Gut 1989; 30: A1501
   Google Scholar
• Lebrec D, Bernuau J, Rueff B, Benhamou JP. Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis. N Engl J Med 1982; 307: 560
   PubMedGoogle Scholar
• Paquet KH. Prophylactic endoscopic sclerosing treatment of esophageal wall in varices: a prospective controlled randomised trial. Endoscopy 1982; 14: 4–5
   PubMed Web of Science ®Google Scholar
• Witzel L, Wolbergs E, Merki H. Prophylactic endoscopic sclerotherapy of esophageal varices; a prospective controlled trial. Lancet 1985; 1: 773–775
   PubMed Web of Science ®Google Scholar
• Koch H, Hennig H, Grim H, Soehendra N. Prophylactic sclerosing of esophageal varices: results of a prospective controlled trial. Endoscopy 1986; 18: 40–43
   PubMedGoogle Scholar
• Sauerbruch T, Wotzka R, Kopcke W, et al. Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988; 319: 8–15
   PubMed Web of Science ®Google Scholar
• Triger D R, Johnston AG. Prophylactic sclerotherapy of esophageal varices: a preliminary report. Gut 1985; 26: A102
   Google Scholar
• Gregory P, Hartigan P, Amodeo D, et al. Prophylactic sclerotherapy for variceal bleeding: preliminary results of a controlled clinical trial. Gastroenterology 1987; 92: 1414
   Web of Science ®Google Scholar
• Santangelo W C, Dueno M I, Estes B L, Krejs GJ. Prophylactic sclerotherapy of large esophageal varices. N Engl J Med 1988; 318: 814–818
   PubMed Web of Science ®Google Scholar
• Rector W G, Reynolds TB. Risk factors for haemorrhage from oesophageal varices and acute gastric erosions. Clinics in gastroenterology, JP Benhamou, D Lebrec. WB Saunders, London 1985
   Google Scholar
• Hosking S W, Kennedy H J, Seddon I, Triger DR. The role of propranolol in congestive gastropathy of portal hypertension. Hepatology 1987; 7: 437–441
   PubMed Web of Science ®Google Scholar
• Westaby D, Hayes P C, Gimson A ES, et al. Controlled trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989; 9: 274–277
   PubMed Web of Science ®Google Scholar
• Paquet H J, Feussner H. Endoscopic sclerosis and oesophageal balloon tamponade in acute haemorrhage from oesophagogastric varices: a prospective controlled trial. Hepatology 1985; 5: 580–583
   PubMed Web of Science ®Google Scholar
• Larson A W, Cohen H, Zweiban B, et al. Acute oesophageal variceal sclerotherapy. JAMA 1986; 255: 497–500
   PubMed Web of Science ®Google Scholar
• Westaby D, Williams R. The status of sclerotherapy for variceal bleeding in 1990. Am J Surg 1990; 160: 32–36
   PubMed Web of Science ®Google Scholar
• Bernuau J, Rueff B. Treatment of acute variceal bleeding. Clinics in gastroenterology, JP Benhamou, D Lebrec. WB Saunders, London 1985
   Google Scholar
• Gimson A ES, Westaby D, Williams R. Endoscopic sclerotherapy and management of gastric variceal haemorrhage. Gut 1989; 30: A1497
   Google Scholar
• Vlavianos P, Gimson A ES, Westaby D, Williams R. Balloon tamponade in variceal bleeding: use and misuse. Br Med J 1989; 298: 1158
   PubMedGoogle Scholar
• Groszmann R J, Kravetz D, Bosch J, et al. Nitroglycerin improves the haemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 3: 757–762
   Google Scholar
• Gelman S, Ernst EA. Nitroprusside prevents adverse haemodynamic effects of vasopressin. Arch Surg 1978; 113: 1465–1466
   PubMedGoogle Scholar
• Mac Mathuna P, Foley B, O'Reilly T, Keeling P WN, Feely J. Vasopressin-nifedipine: a favourable haemodynamic interaction in cirrhosis and portal hypertension. Br J Clin Pharmacol 1988; 25: 621–622
   Google Scholar
• Gimson A ES, Westaby D, Hegarty J, Watson A, Williams R. A randomised trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal haemorrhage. Hepatology 1986; 6: 41, CW13
   Google Scholar
• Bosch J, Groszmann R J, Garcia-Pagen J C, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal haemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10: 962–968
   PubMed Web of Science ®Google Scholar
• Freeman J G, Cobden F, Lishman A H, Record CO. Controlled trial of terlipressin [glypressin] versus vasopressin in the early treatment of oesophageal varices. Lancet 1982; 2: 66–67; 99
   PubMed Web of Science ®Google Scholar
• Kravetz D, Bosch J, Teres J, et al. Comparison of intravenous somatostatin and vasopressin infusion in treatment of acute variceal haemorrhage. Hepatology 1984; 4: 442–446
   PubMed Web of Science ®Google Scholar
• Valenzuela J E, Schubert T, Fogel M R, et al. A multicenter, randomised, double-blind trial of somatostatin in the management of acute haemorrhage from oesophageal varices. Hepatology 1989; 10: 958–961
   PubMed Web of Science ®Google Scholar
• Hoskings S W, Doss W, El-Zeiny H, Robinson P, Barsoum M S, Johnson AG. Pharmacological constriction of the lower oesophageal sphincter: a simple method of arresting variceal haemorrhage. Gut 1988; 28: 1098–1102
   Google Scholar
• Burroughs A K, Hamilton G, Phillips A, Mez-Zanotte G, McLntyre N, Hobbs K EF. A comparison of sclerotherapy with staple transection of the oesophagus for the emergency control of bleeding from oesophageal varices. N Engl J Med 1989; 321: 857–862
   PubMed Web of Science ®Google Scholar
• Neuberger JM. Transplantation for alcoholic liver disease [Editorial]. Br Med J 1989; 299: 693
   PubMedGoogle Scholar
• Iwatsuki S, Starzl T, Todo S, et al. Liver transplantation in the treatment of bleeding oesophageal varices. Surgery 1988; 104: 697–705
   PubMed Web of Science ®Google Scholar
• Barsoum M S, Bolous F I, El-Rooby A A, Rizk-Allah M A, Ibrahim AS. Tamponade and injection sclerotherapy in the management of bleeding oesophageal varices. Br J Surg 1982; 69: 76–78
   PubMed Web of Science ®Google Scholar
• The Copenhagen Oesophageal Project Varices Sclerotherapy. Sclerotherapy after the first variceal haemorrhage in cirrhosis. A randomised multicenter trial. N Engl J Med 1984; 311: 1594–1600
   PubMedGoogle Scholar
• Terblanche J, Bornman P C, Kahn D, Jonker M A, Campbell J AH, Kirsch R. Failure of repeated injection sclerotherapy to improve long-term survival afer oesophageal bleeding. A five-year prospective controlled clinical trial. Lancet 1983; 2: 1328–1332
   PubMed Web of Science ®Google Scholar
• Westaby D, MacDougall B R, Williams R. Improved survival following injection sclerotherapy for oesophageal varices: final analysis of a controlled trial. Hepatology 1985; 5: 827–830
   PubMed Web of Science ®Google Scholar
• Korula J, Balart L A, Radvan G, et al. A prospective randomised controlled trial of chronic oesophageal variceal sclerotherapy. Hepatology 1985; 5: 584–589
   PubMed Web of Science ®Google Scholar
• Soderland C, Ihre T. Endoscopic sclerotherapy versus conservative management of bleeding oesophageal varices. Acta Chir Scand 1985; 151: 449–456
   PubMedGoogle Scholar
• Infante-Rivard C, Esnaola S, Villeneuve JP. Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a metaanalysis. Gastroenterology 1989; 96: 1087–1092
   PubMed Web of Science ®Google Scholar
• Van Stiegmann G, Goff JS. Endoscopic oesophageal varix ligation: preliminary clinical experience. Gastrointest Endosc 1988; 34: 113–117
   PubMedGoogle Scholar
• Westaby D, Melia W, Hegerty J, Gimson A ES, Stellon A J, Williams R. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology 1986; 6: 673–675
   PubMed Web of Science ®Google Scholar
• Poison R J, Westaby D, Gimson A ES, et al. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for oesophageal varices. Hepatology 1989; 10: 279–283
   PubMedGoogle Scholar
• Burroughs A K, d'Heygere, Phillips F., Dooley A. J, Epstein O, McLntyre N. Prospective randomised trial of chronic sclerotherapy for prevention of variceal rebleeding, with use of the same protocol to treat rebleeding in all patients: a final report. Gut 1989; 30: A1506
   Google Scholar
• Teres J, Bordas J M, Bravo, et al. Sclerotherapy versus distal spleno-renal shunt in the elective treatment of variceal haemorrhage: a randomised controlled trial. Hepatology 1987; 7: 430–436
   PubMed Web of Science ®Google Scholar
• Warren W D, Henderson J M, Millikan W J, et al. Distal spleno-renal versus endoscopic sclerotherapy for long-term management of variceal bleeding. Ann Surg 1986; 203: 454–461
   PubMed Web of Science ®Google Scholar
• Rikkers L F, Burnett D A, Valentine G D, Buchi K N, Cornier RA. Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of randomised trial. Ann Surg 1987; 206: 261–269
   PubMed Web of Science ®Google Scholar
• Cello J P, Grendall J H, Crass R A, Weber T E, Trunkey DD. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal haemorrhage. N Engl J Med 1987; 316: 11–15
   PubMed Web of Science ®Google Scholar
• Korula J, Yellin A, Yamada S, Weiner J, Cohen H, Reynolds TB. A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portal systemic shunt for variceal haemorrhage. Gastroenterology 1987; 92: 1745
   Google Scholar
• Lebrec D, Poynard T, Bernuau J, et al. A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4: 355–358
   PubMed Web of Science ®Google Scholar
• Poynard T, Lebrec D, Hillon P, et al. Propranolol for recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. J Hepatol 1987; 7: 447–451
   Google Scholar
• Caujolle B, Ballet F, Poupon R. Relationship among β-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis. Scand J Gastroenterol 1988; 23: 925–930
   PubMed Web of Science ®Google Scholar
• Shaw B W, Wood R P, Stratt R J, Pillen T J, Langnas AN. Stratifying the causes of death in liver transplant recipients. Arch Surg 1989; 124: 895–900
   PubMedGoogle Scholar
• Donovan J P, Zetterman R K, Burnett D A, Sorrel MF. Pre-operative evaluation, preparation and timing of orthotopic liver transplantation in the adult. Semin Liver Dis 1989; 9: 168–175
   PubMed Web of Science ®Google Scholar
• Villeneuve JP. Prognostic factors for rebleeding in patients with variceal haemorrhage. Methodology and reviews of clinical trials in portal hypertension, AK Burroughs. Excerpta Medica, Amsterdam 1987; 161–166
   Google Scholar